Recently, a longitudinal study of 88 CML patients showed that dasatinib induced down-regulation of NKG2A on PB NK cells, leading to enhanced cytotoxicity and favoring CML patients’ clinical response. The gene discussed is KLRC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.